title: [The PROMET study: Prophylaxis for venous thromboembolic disease in at-risk patients hospitalized in Algeria].
abstract: PROMET is an observational study aimed to assess the management of patients at venous thromboembolism risk in the Algerian hospitals and to evaluate the proportion of at-risk patients treated with an adequate prophylaxis. Following the ENDORSE study achieved five years before with a similar protocol, PROMET included 435hospitalized patients (229 in medical units and 206 in surgical units). Compared to the ENDORSE results, the PROMET data reflect progress in the management of venous thromboembolism: 73.3% of at-risk patients received prophylaxis (57.6% of medical patients and 90.8% of surgical patients). In 93.1% of cases, this prophylaxis was provided by a low molecular weight heparin, mainly at the dose of one injection per day. In medical population, the prescription was triggered by long-term immobilization (P=0.01; OR=5.8 95%CI [1.5-23.0]), associated risk factors (P=0.025; OR=4.13 [1.2-14.2]) and the cause of hospitalization (P=0.056). In surgical departments, the therapeutic decision depended on the nature of the surgical intervention and was influenced by the presence of a contraindication for prophylaxis (P<0.001; OR=0.02 [0.00-0.14]) or a high hemorrhagic risk (P<0.001; OR=0.02). The assessment and management of thromboembolic risk were in accordance with ACCP recommendations for surgical patients. However efforts are needed for medical patients for whom the risk is underestimated and insufficiently supported. Unlike surgery where procedures are well established, there are real difficulties in medicine to define the at-risk patients who will benefit from thromboprophylaxis. The process of preventive treatment (particularly the optimal duration) needs to be clarified.
authors.affiliation: Service de médecine interne, établissement public hospitalier El Biar, Alger, Algérie. Electronic address: guermaz@yahoo.fr.
authors.forename: R
authors.initials: R
authors.lastname: Guermaz
authors.affiliation: Département des affaires médicales, Sanofi-Aventis Alger, Alger, Algérie.
authors.forename: S
authors.initials: S
authors.lastname: Belhamidi
authors.affiliation: Département des affaires médicales, Sanofi-Aventis Alger, Alger, Algérie.
authors.forename: A
authors.initials: A
authors.lastname: Amarni
mesh_terms: D000328:Adult; D000368:Aged; D000462:Algeria; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D000075202:Contraindications; D003430:Cross-Sectional Studies; D003953:Diagnosis-Related Groups; D019468:Disease Management; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006748:Hospital Departments / Q000706:statistics & numerical data; D006801:Humans; D007103:Immobilization / Q000009:adverse effects; D007297:Inpatients / Q000706:statistics & numerical data*; D008297:Male; D008511:Medicine; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology / Q000517:prevention & control; D012307:Risk Factors; D019851:Thrombophilia / Q000188:drug therapy* / Q000209:etiology; D054556:Venous Thromboembolism / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight
keywords: Hemorrhagic risk; Risque hémorragique; Risque thrombotique; Thromboprophylaxie; Thromboprophylaxis; Thrombotic risk